The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
<< First    < Prev 10    11 to 20 of 2121    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

Solid Tumor Rules (2018)/Histology--Lung:  What is the histology code of invasive moderately differentiated adenocarcinoma, predominantly papillary subtype, with minor acinar and lepidic subtypes?  See Discussion.

Final May 29 2019

Solid Tumor Rules (2018)/Histology--Breast: How is the histology coded and which H Rule applies for a single tumor with final diagnosis of invasive mammary carcinoma and College of American Pathologists (CAP) synoptic report states, Histologic type: Invasive cribriform carcinoma with no mention of a tumor percentage? See Discussion.

Final May 28 2019

Solid Tumor Rules/Multiple Primaries--Breast: How many primaries should be abstracted for simultaneously diagnosed non-contiguous invasive duct carcinoma and mucinous carcinoma? Does rule M12 apply since the two histologies are on different rows of Table 3 of the Breast Solid Tumor Rules?  See Discussion.

Final May 22 2019

First Course of Treatment/Hormone Therapy--Breast:  Is hormone therapy (HT) prescribed for invasive ductal carcinoma of the right breast coded as treatment for lobular carcinoma in situ (LCIS) of the left breast even though the treatment plan for the LCIS was documented as surveillance?  See Discussion.

Final May 21 2019

Reportability/Histology--Vulva/Penis:  Are differentiated penile intraepithelial neoplasia (C60._) and differentiated vulvar intraepithelial neoplasia (C51._) reportable for cases diagnosed 2018+?  See Discussion.



Final May 08 2019

Reportability/Histology--Penis: Is a diagnosis of undifferentiated penile intraepithelial neoplasia (PeIN) reportable for cases diagnosed in any year? See Discussion.

Final May 08 2019

Neoadjuvant therapy/Pathologic tumor size--Breast:  When a patient with invasive breast cancer is started on neoadjuvant therapy and  at surgery is found to have only residual in-situ disease, do we record the size of the in-situ tumor for Pathologic Tumor Size?  See Discussion.

Final Aug 09 2019

Summary Stage 2018--Lung: Are ground-glass lung nodules coded as distant for Summary Stage? See Discussion.

Final Apr 23 2019

Primary site--Head & Neck:  Are cases with positive cervical lymph nodes that are EBV positive (EBV+) coded to the nasopharynx, and cases with positive cervical lymph nodes that are p16 positive (p16+) coded to the oropharynx, when no primary site is identified? See Discussion.

Final Apr 23 2019

Summary Stage 2018/Extension--Prostate: Can imaging be used to code SEER Summary Stage 2018? MRI shows tumor involved the seminal vesicles and the patient did not have surgery. AJCC does not use imaging to clinically TNM stage a prostate case.

Final Apr 22 2019
< Prev 10    Next 10 >